Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Anderson

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
Human Molecular Genetics|December 3, 2003
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretaseJoanna L Jankowsky, Daniel J Fadale, Jeffrey Anderson, et al.
Autism Research : Official Journal of the International Society for Autism Research|February 26, 2013
Longitudinal Heschl's gyrus growth during childhood and adolescence in typical development and autismMolly D Prigge, Erin D Bigler, P Thomas Fletcher, et al.
The Journal of Pediatrics|July 26, 2011
Factors affecting growth in infants with single ventricle physiology: a report from the Pediatric Heart Network Infant Single Ventricle TrialRichard V Williams, Victor Zak, Chitra Ravishankar, et al.
Journal of Clinical and Experimental Neuropsychology|August 30, 2013
Neuropsychological investigation of motor impairments in autismTyler C Duffield, Haley G Trontel, Erin D Bigler, et al.
Journal of Hepatology|November 1, 2019
Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552]Thomas Yau, Chiun Hsu, Tae-You Kim, et al.
Journal of Hepatology|June 10, 2019
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysisThomas Yau, Chiun Hsu, Tae-You Kim, et al.
Plos One|May 30, 2013
A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infectionDavid Gardiner, Jay Lalezari, Eric Lawitz, et al.
Open Heart|April 19, 2019
Mechanical performance and healing patterns of the novel sirolimus-eluting bioresorbable Fantom scaffold: 6-month and 9-month follow-up by optical coherence tomography in the FANTOM II studyJo Krogsgaard Simonsen, Emil Nielsen Holck, Didier Carrié, et al.
Cardiology in the Young|December 21, 2018
Cardiac Networks United: an integrated paediatric and congenital cardiovascular research and improvement networkMichael Gaies, Jeffrey Anderson, Alaina Kipps, et al.
Lancet (London, England)|April 25, 2017
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialAnthony B El-Khoueiry, Bruno Sangro, Thomas Yau, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Human Molecular Genetics|December 3, 2003
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretaseJoanna L Jankowsky, Daniel J Fadale, Jeffrey Anderson, et al.
Autism Research : Official Journal of the International Society for Autism Research|February 26, 2013
Longitudinal Heschl's gyrus growth during childhood and adolescence in typical development and autismMolly D Prigge, Erin D Bigler, P Thomas Fletcher, et al.
The Journal of Pediatrics|July 26, 2011
Factors affecting growth in infants with single ventricle physiology: a report from the Pediatric Heart Network Infant Single Ventricle TrialRichard V Williams, Victor Zak, Chitra Ravishankar, et al.
Journal of Clinical and Experimental Neuropsychology|August 30, 2013
Neuropsychological investigation of motor impairments in autismTyler C Duffield, Haley G Trontel, Erin D Bigler, et al.
Journal of Hepatology|November 1, 2019
Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552]Thomas Yau, Chiun Hsu, Tae-You Kim, et al.
Journal of Hepatology|June 10, 2019
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysisThomas Yau, Chiun Hsu, Tae-You Kim, et al.
Plos One|May 30, 2013
A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infectionDavid Gardiner, Jay Lalezari, Eric Lawitz, et al.
Open Heart|April 19, 2019
Mechanical performance and healing patterns of the novel sirolimus-eluting bioresorbable Fantom scaffold: 6-month and 9-month follow-up by optical coherence tomography in the FANTOM II studyJo Krogsgaard Simonsen, Emil Nielsen Holck, Didier Carrié, et al.
Cardiology in the Young|December 21, 2018
Cardiac Networks United: an integrated paediatric and congenital cardiovascular research and improvement networkMichael Gaies, Jeffrey Anderson, Alaina Kipps, et al.
Lancet (London, England)|April 25, 2017
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialAnthony B El-Khoueiry, Bruno Sangro, Thomas Yau, et al.
Pageof 9